Repligen Co. (NASDAQ:RGEN) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Repligen Co. (NASDAQ:RGEN) have received a consensus rating of “Moderate Buy” from the eleven research firms that are presently covering the stock, Marketbeat reports. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $190.25.

RGEN has been the topic of a number of analyst reports. Wolfe Research assumed coverage on Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating on the stock. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday, November 22nd. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a research report on Thursday, September 26th. Wells Fargo & Company assumed coverage on shares of Repligen in a research note on Tuesday, August 27th. They set an “overweight” rating and a $180.00 target price for the company. Finally, Benchmark reaffirmed a “hold” rating on shares of Repligen in a report on Monday, August 5th.

Insider Buying and Selling at Repligen

In other news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the transaction, the director now owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. The trade was a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Repligen

Hedge funds and other institutional investors have recently bought and sold shares of the company. Toronto Dominion Bank lifted its stake in shares of Repligen by 1.5% in the 2nd quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company’s stock worth $656,000 after acquiring an additional 75 shares during the period. DekaBank Deutsche Girozentrale boosted its holdings in Repligen by 1.1% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company’s stock valued at $982,000 after purchasing an additional 89 shares in the last quarter. MML Investors Services LLC increased its position in Repligen by 2.7% during the 3rd quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock worth $503,000 after purchasing an additional 89 shares during the period. Ballentine Partners LLC raised its stake in shares of Repligen by 6.2% during the 3rd quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company’s stock worth $269,000 after buying an additional 105 shares in the last quarter. Finally, Diversified Trust Co lifted its holdings in shares of Repligen by 3.7% in the 2nd quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company’s stock valued at $372,000 after buying an additional 106 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Price Performance

Shares of RGEN opened at $150.54 on Friday. The firm has a 50-day simple moving average of $140.98 and a two-hundred day simple moving average of $142.85. The stock has a market cap of $8.43 billion, a PE ratio of -406.86, a P/E/G ratio of 4.52 and a beta of 0.96. Repligen has a 1-year low of $113.50 and a 1-year high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. During the same quarter last year, the firm earned $0.23 EPS. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. As a group, analysts forecast that Repligen will post 1.52 EPS for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.